Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia
Andrew D. Krystal, Diego A. Pizzagalli, Moria J. Smoski, et al.
Nature Medicine (2020) Vol. 26, Iss. 5, pp. 760-768
Open Access | Times Cited: 186

Showing 1-25 of 186 citing articles:

Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions
Daniel F. Levey, Murray B. Stein, Frank R. Wendt, et al.
Nature Neuroscience (2021) Vol. 24, Iss. 7, pp. 954-963
Open Access | Times Cited: 317
The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Gerard Sanacora, Zhen Yan, Maurizio Popoli
Nature reviews. Neuroscience (2021) Vol. 23, Iss. 2, pp. 86-103
Closed Access | Times Cited: 127
Research Domain Criteria (RDoC): Progress and Potential
Bruce N. Cuthbert
Current Directions in Psychological Science (2022) Vol. 31, Iss. 2, pp. 107-114
Open Access | Times Cited: 114
Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?
Diego A. Pizzagalli
American Journal of Psychiatry (2022) Vol. 179, Iss. 7, pp. 458-469
Open Access | Times Cited: 103
Revisiting the seven pillars of RDoC
Sarah E. Morris, Charles A. Sanislow, Jenni Pacheco, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 102
The Hierarchical Taxonomy of Psychopathology (HiTOP) in psychiatric practice and research
Roman Kotov, David C. Cicero, Christopher Conway, et al.
Psychological Medicine (2022) Vol. 52, Iss. 9, pp. 1666-1678
Closed Access | Times Cited: 91
New and emerging approaches to treat psychiatric disorders
Katherine W. Scangos, Matthew W. State, Andrew H. Miller, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 317-333
Closed Access | Times Cited: 74
Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety
Leonardo Tozzi, Xue Zhang, Adam Pines, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2076-2087
Open Access | Times Cited: 61
Positive affect treatment targets reward sensitivity: A randomized controlled trial.
Michelle G. Craske, Alicia E. Meuret, Aileen Echiverri-Cohen, et al.
Journal of Consulting and Clinical Psychology (2023) Vol. 91, Iss. 6, pp. 350-366
Closed Access | Times Cited: 60
Alcohol Use Disorder Treatment: Problems and Solutions
George F. Koob
The Annual Review of Pharmacology and Toxicology (2024) Vol. 64, Iss. 1, pp. 255-275
Open Access | Times Cited: 28
Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
Sabrina Wong, Gia Han Le, Lee Phan, et al.
Journal of Affective Disorders (2024) Vol. 356, pp. 684-698
Closed Access | Times Cited: 18
Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study
Mark E. Schmidt, Iva Kezic, Vanina Popova, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 9, pp. 1437-1447
Open Access | Times Cited: 17
Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry
Andrew H. Miller, Michael Berk, Gilles Bloch, et al.
Brain Behavior and Immunity (2025) Vol. 125, pp. 319-329
Closed Access | Times Cited: 3
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges
Michael J. Lucido, Boadie W. Dunlop
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 161-161
Open Access | Times Cited: 2
Characterizing anhedonia: A systematic review of neuroimaging across the subtypes of reward processing deficits in depression
Alessandra Borsini, Amelia St John Wallis, Patricia A. Zunszain, et al.
Cognitive Affective & Behavioral Neuroscience (2020) Vol. 20, Iss. 4, pp. 816-841
Open Access | Times Cited: 134
Assessment of Anhedonia in Adults With and Without Mental Illness
Martin Trøstheim, Marie Eikemo, R. Meir, et al.
JAMA Network Open (2020) Vol. 3, Iss. 8, pp. e2013233-e2013233
Open Access | Times Cited: 101
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)
Diego A. Pizzagalli, Moria J. Smoski, Yuen‐Siang Ang, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 10, pp. 1656-1663
Open Access | Times Cited: 92
Novel drug developmental strategies for treatment‐resistant depression
Éva Borbély, Mária Simon, Eberhard Fuchs, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 6, pp. 1146-1186
Open Access | Times Cited: 71
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Jack W. Scannell, Jim Bosley, John A. Hickman, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 12, pp. 915-931
Open Access | Times Cited: 68
Release of endogenous dynorphin opioids in the prefrontal cortex disrupts cognition
Antony D. Abraham, Sanne M. Casello, Selena S. Schattauer, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 13, pp. 2330-2339
Open Access | Times Cited: 60
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial
Sara Costi, Laurel S. Morris, Katherine Kirkwood, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 5, pp. 437-446
Open Access | Times Cited: 56
The opioid system in depression
Luke A. Jelen, James Stone, Allan H. Young, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104800-104800
Open Access | Times Cited: 53
Anhedonia, Hyperkatifeia, and Negative Reinforcement in Substance Use Disorders
George F. Koob
Current topics in behavioral neurosciences (2022), pp. 147-165
Closed Access | Times Cited: 52
Personality neuroscience: An emerging field with bright prospects
Colin G. DeYoung, Roger E. Beaty, Erhan Genç, et al.
Personality Science (2022) Vol. 3
Open Access | Times Cited: 42
Modulation of 5-HT release by dynorphin mediates social deficits during opioid withdrawal
Matthew B. Pomrenze, Daniel F. Cardozo Pinto, Peter A. Neumann, et al.
Neuron (2022) Vol. 110, Iss. 24, pp. 4125-4143.e6
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top